3 May 2016

PRINT-AID project approved under Horizon 2020 MSCA-ITN-2016 call. The objective is to set-up a new European education platform to guide and inspire young researchers in the intersectoral exploration of innovative routes to
counteract microbial biofilms by fabricating anti-infective, tailored, 3D-printed medical devices. LMPH is the partner in this consortium.

17 July 2015

The ProCure consortium obtained an IWT-SBO grant to define the future of probiotics for upper repiratory tract diseases! Prof. Filip Kieken (LPT and ADDN partner) is member of this consortium. 

1 December 2014

UAMC is partner of the approved horizon 2020 ITN project Integrate: Interdisciplinary Training Network for Validation of Gram-NegativeAntibacterial Targets

1 September 2014

The new ADDN consortium is successfully approved and The Laboratory of Pharmaceutical Technology and Biopharmacy, The Laboratory of Natural Products and Food research and analysis and the Laboratory of pathophysiology are new officially partners of the network.

5 May 2014

LMPH and LMB and partners obtained a Hercules grant to set up a platform for high-speed refrigerated, preparative ultracentrifugation, automated gradient formation and fraction collection and analysis.

3 April 2014

The Lab. of Microbiology, Parasitology and Hygine (LMPH) and the Lab. of Medicinal Chemistry (UAMC), both members of ADDN, are partners in a new approved FP7 project: Parasite-specific nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases. More information on the PDE4NPD project can be found here.

1 June 2013

Dr. Jurgen Joossens successfully obtained an IWT innovation mandate to further develop SerThera, an academic platform spun out of ChemProTools, which is aimed at discovering novel potent and selective serine protease inhibitors. Major progress has been achieved and the possibility of developing the SerThera platform into a spin-off company is being studied.

8 February 2013

The Laboratory of Pharmaceutcial Technology and Biopharmacy joins ADDN.

The expertise of the Laboratory of Pharmaceutical Technology and Biopharmacy will support the ADDN preclinical development projects substantially! Formulations aspects can now be investigated much earlier in the discovery phase and will support a beneficial read-out in in vivo experiments. 

3 January 2013

UAMC is coordinator of a new FP7-ITN project: OpenMedChem

Attracting and training a new generation of Medicinal Chemists in an Industry/Academia open innovation environment for antimycobacterial drug discovery by offering a set of unique complementary training benefits for young scientists.

Three researchers will carry out PhD research during consecutive training phases in academia (University of Antwerp, Belgium) and Industry (GSK DDW, Spain).

3 January 2013

LMPH is partner in a new IWT-SBO project: RESIST

Together with partners of UGent and KU Leuven the project will develop new strategies to target sociomicrobiological processes to circumvent antimicrobial resistance. 

8 February 2012

ChemProTools official kick off

Our Medchem partner (UAMC) succesfully obtained an IWT-SBO project. The major aim of the ChemProTools project is the formation of an unique and generic platform around the chemical probe technology.

15 June 2011

New purification facility is operational

ADDN, Natura and ORGANICA have succesfully implemented an open-access purification platform, which is built around different flash systems, MS-triggered LC-prep and SFC-prep.

This facility was funded by a joint Hercules Grant. 

12 February 2010

UAMC, the Laboratory of Medicinal Chemistry is partner in the FP7 project CHAARM

The CHAARM project aims to develop anti-HIV microbicides - products that could reduce the transmission of HIV by sexual intercourse.

1 September 2009

UAMC, the Laboratory of Medicinal Chemistry and the Laboratory of Medical Biochemistry moved to brand new research facilities. 

The chemistry unit has now place for 20 to 25 chemists and has access to state of the art research equipment.

3 July 2009

The partners of ADDN have successfully acquired funding from the Hercules organisation. A 400 MHz NMR (Bruker) and a LC-MS system (Xevo, Waters) will support the (bio)analytical part of our drug discovery projects.  

10 January 2009

LMPH and the Laboratory of Medical Biochemistry, both members of ADDN, are partners in two approved FP7 projects: 
LMPH: EU 7th FP: KALADRUG,  New tools for monitoring drug resistance and treatment reponse in Visceral Leishmaniasis in the Indian subcontinent 01/10/2008-31/12/2012 
Laboratory of Medical Biochemistry: EU 7th FP: NEUROPRO, A.M. Lambeir – Oligopeptidase inhibitors in brain function and dysfunction: towards new therapeutic strategies for neuroprotection.  01/10/2008 - 30/09/2012

7 April 2008

ADDN has started with the implemenation of an electronic lab notebook system in their laboratories.

E-Notebook" developed and supplied by CambridgeSoft Corporation is software used to record electronically what until recently had been written into paper experiment notebooks by laboratory researchers. Not only facilitating the progress of research through knowledge sharing but a tool used to periodically create reports based on electronic experimental data and ease the intricated process of data gathering necessary for patent applications.